- Home
- MHH vs PRLD Comparison
MHH vs PRLD Comparison
Compare MHH & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MHH | PRLD |
|---|---|---|
| Founded | 1986 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.9M | 69.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MHH | PRLD |
|---|---|---|
| Price | $6.87 | $1.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 20.0K | ★ 547.0K |
| Earning Date | 02-18-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $196,657,000.00 | $10,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.50 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 1.24 | ★ 250.00 |
| 52 Week Low | $6.20 | $0.61 |
| 52 Week High | $14.75 | $4.22 |
Technical Indicators
Market Signals| Indicator | MHH | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 44.80 | 46.04 |
| Support Level | $6.80 | $1.90 |
| Resistance Level | $7.34 | $2.20 |
| Average True Range (ATR) | 0.34 | 0.25 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 2.74 | 18.37 |
Price Performance
Historical ComparisonAbout MHH Mastech Digital Inc
Mastech Digital Inc is a provider of Digital Transformation IT Services. The Company offers data & analytics solutions & IT staffing services for both digital & mainstream technologies. The Group has two segments. Its Data & Analytics Services segment delivers specialized data management, data engineering, customer experience consulting, data analytics & cloud services to customers globally. IT Staffing Services segment combines technical expertise with business process experience to deliver a broad range of services in digital & mainstream technologies. The company derives a majority of its revenue from IT staffing services. Geographically, the majority of revenue is generated from the United States.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.